These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 16940276

  • 1. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF, Seymour JF, Hicks RJ, Turner JH.
    J Clin Oncol; 2006 Sep 20; 24(27):4418-25. PubMed ID: 16940276
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.
    J Clin Oncol; 2002 May 15; 20(10):2453-63. PubMed ID: 12011122
    [Abstract] [Full Text] [Related]

  • 3. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL.
    Eur J Nucl Med Mol Imaging; 2005 Oct 15; 32(10):1225-33. PubMed ID: 15937686
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW.
    J Clin Oncol; 2007 Apr 10; 25(11):1396-402. PubMed ID: 17312330
    [Abstract] [Full Text] [Related]

  • 6. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
    Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM.
    Asia Pac J Clin Oncol; 2011 Jun 10; 7(2):136-45. PubMed ID: 21585693
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA.
    J Clin Oncol; 2002 Aug 01; 20(15):3262-9. PubMed ID: 12149300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
    Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF.
    Ann Oncol; 2008 Sep 01; 19(9):1629-33. PubMed ID: 18522934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
    Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, Fisher S, Regan D, Kroll S, Kaminski MS.
    J Nucl Med; 1998 Aug 01; 39(8 Suppl):21S-27S. PubMed ID: 9708567
    [Abstract] [Full Text] [Related]

  • 20. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y, IDEC-C2B8 Study Group.
    Cancer Sci; 2011 Sep 01; 102(9):1698-705. PubMed ID: 21645173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.